Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Ovarian Neoplasms

  Free Subscription


Articles published in Ann Oncol

Retrieve available abstracts of 29 articles:
HTML format



Single Articles


    January 2024
  1. LEDERMANN JA, Matias-Guiu X, Amant F, Concin N, et al
    ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease.
    Ann Oncol. 2024 Jan 29:S0923-7534(23)05103-7. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available


    December 2023
  2. MCNEISH IA, Monk BJ
    Is more of a good thing still a good thing? PARP inhibitor retreatment in high-grade ovarian carcinoma.
    Ann Oncol. 2023;34:1074-1076.
    PubMed    


    October 2023
  3. SESSA C, Paluch-Shimon S
    Reply to the Letter to the Editor 'There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes (in regard to "ESMO Clinical Practice Guideline on risk reduction and screening of cancer in hereditary breast-ovarian canc
    Ann Oncol. 2023 Oct 26:S0923-7534(23)04325-9. doi: 10.1016/j.annonc.2023.
    PubMed    


  4. TJALMA WAA
    There is no place for ovarian cancer screening in hereditary breast-ovarian cancer syndromes.
    Ann Oncol. 2023 Oct 20:S0923-7534(23)04324-7. doi: 10.1016/j.annonc.2023.
    PubMed    


  5. PUJADE-LAURAINE E, Selle F, Scambia G, Asselain B, et al
    Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
    Ann Oncol. 2023 Oct 3:S0923-7534(23)04007-3. doi: 10.1016/j.annonc.2023.09.3110.
    PubMed     Abstract available


    August 2023
  6. GONZALEZ-MARTIN A, Harter P, Leary A, Lorusso D, et al
    Newly diagnosed and relapsed epithelial ovarian cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
    Ann Oncol. 2023 Aug 10:S0923-7534(23)00797-4. doi: 10.1016/j.annonc.2023.
    PubMed    


    May 2023
  7. RAY-COQUARD I, Leary A, Pignata S, Cropet C, et al
    Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.
    Ann Oncol. 2023 May 19:S0923-7534(23)00686-5. doi: 10.1016/j.annonc.2023.
    PubMed     Abstract available


    December 2022
  8. LOVEDAY C, Garrett A, Law P, Hanks S, et al
    Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes.
    Ann Oncol. 2022;33:1318-1327.
    PubMed     Abstract available


    November 2022
  9. LABIDI-GALY SI, Rodrigues M, Sandoval JL, Kurtz JE, et al
    Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
    Ann Oncol. 2022 Nov 28:S0923-7534(22)04733-0. doi: 10.1016/j.annonc.2022.
    PubMed     Abstract available


    October 2022
  10. SESSA C, Balmana J, Bober SL, Cardoso MJ, et al
    Risk reduction and screening of cancer in hereditary breast-ovarian cancer syndromes: ESMO Clinical Practice Guideline.
    Ann Oncol. 2022 Oct 19. pii: S0923-7534(22)04193.
    PubMed    


    August 2022
  11. KRISTELEIT RS, Moore K
    Life after SOLO-2: Is Olaparib really inducing platinum resistance in BRCA-mutated (BRCAm), PARP inhibitor (PARPi) resistant, recurrent ovarian cancer?
    Ann Oncol. 2022 Aug 11. pii: S0923-7534(22)03867.
    PubMed    


    June 2022
  12. FRENEL JS, Kim JW, Aryal N, Asher R, et al
    Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
    Ann Oncol. 2022 Jun 27. pii: S0923-7534(22)01740.
    PubMed     Abstract available


    April 2022
  13. COLEMAN RL
    For Ovarian Cancer PARPi maintenance therapy: more is better, right?
    Ann Oncol. 2022 Apr 7. pii: S0923-7534(22)00681.
    PubMed    


    February 2022
  14. FRANCIS KE, Kim SI, Friedlander M, Gebski V, et al
    The impact of olaparib dose reduction and treatment interruption on treatment outcome in the SOLO2/ENGOT-ov21 platinum-sensitive recurrent ovarian cancer.
    Ann Oncol. 2022 Feb 24. pii: S0923-7534(22)00338.
    PubMed     Abstract available


    January 2022
  15. DALMARTELLO M, La Vecchia C, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2022 with focus on ovarian cancer.
    Ann Oncol. 2022 Jan 13. pii: S0923-7534(21)04881.
    PubMed     Abstract available


  16. MOORE KN, du Bois A
    Homologous recombination deficiency testing in first-line ovarian cancer.
    Ann Oncol. 2022 Jan 8. pii: S0923-7534(22)00004.
    PubMed    


    November 2021
  17. VERGOTE I, Gonzalez-Martin A, Ray-Coquard I, Harter P, et al
    European Experts Consensus: BRCA/Homologous Recombination Deficiency Testing in First-Line Ovarian Cancer.
    Ann Oncol. 2021 Nov 30. pii: S0923-7534(21)04828.
    PubMed     Abstract available


    August 2021
  18. MARTIN JE, Khalife-Hachem S, Grinda T, Kfoury M, et al
    Therapy-related myeloid neoplasms following treatment with PARP inhibitors: new molecular insights.
    Ann Oncol. 2021;32:1046-1048.
    PubMed    


    July 2021
  19. COLOMBO N, Ledermann JA
    Updated treatment recommendations for newly diagnosed epithelial ovarian carcinoma from the ESMO Clinical Practice Guidelines.
    Ann Oncol. 2021 Jul 14. pii: S0923-7534(21)02182.
    PubMed    


  20. DI VINCENZO A, Andrisani A, Vettor R, Rossato M, et al
    Estrogen and COVID-19: friend or foe?
    Ann Oncol. 2021;32:933-934.
    PubMed    


    June 2021
  21. MIRZA MR, Coleman RL, Gonzalez-Martin A, Moore KN, et al
    Corrigendum to 'The forefront of ovarian cancer therapy: update on PARP inhibitors': [Annals of Oncology 31 (2020) 1148-1159].
    Ann Oncol. 2021 Jun 2. pii: S0923-7534(21)02020.
    PubMed    


    March 2021
  22. BAERT T, Ferrero A, Sehouli J, O Donnell DM, et al
    The Systemic Treatment of Recurrent Ovarian Cancer revisited.
    Ann Oncol. 2021 Mar 3. pii: S0923-7534(21)00155.
    PubMed     Abstract available


  23. MOORE KN, Oza AM, Colombo N, Oaknin A, et al
    Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.
    Ann Oncol. 2021 Mar 2. pii: S0923-7534(21)00157.
    PubMed     Abstract available


    January 2021
  24. MONTOPOLI M, Zorzi M, Cocetta V, Prayer-Galetti T, et al
    Clinical outcome of SARS-CoV-2 infection in breast and ovarian cancer patients underwent anti-estrogenic therapy.
    Ann Oncol. 2021 Jan 29. pii: S0923-7534(21)00097.
    PubMed    


  25. WU XH, Zhu JQ, Yin RT, Yang JX, et al
    Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer using an individualized starting dose (NORA): a randomized, double-blind, placebo-controlled phase 3 trial.
    Ann Oncol. 2021 Jan 13. pii: S0923-7534(21)00008.
    PubMed     Abstract available


  26. TOBALINA L, Armenia J, Irving E, O'Connor MJ, et al
    A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance.
    Ann Oncol. 2021;32:103-112.
    PubMed     Abstract available


    December 2020
  27. PILIE PG, George A, Yap TA
    Patient selection biomarker strategies for PARP inhibitor therapy.
    Ann Oncol. 2020;31:1603-1605.
    PubMed    


    September 2020
  28. MILLER RE, Leary A, Scott CL, Serra V, et al
    ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer.
    Ann Oncol. 2020 Sep 28. pii: S0923-7534(20)42164.
    PubMed     Abstract available


    February 2020
  29. WAKS AG, Cohen O, Kochupurakkal B, Kim D, et al
    Reversion and non-reversion mechanisms of resistance to PARP inhibitor or platinum chemotherapy in BRCA1/2-mutant metastatic breast cancer.
    Ann Oncol. 2020 Feb 20. pii: S0923-7534(20)36055.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.